Zaltrap

Novartis sues Regeneron over manufacturing methods
Novartis sues Regeneron over manufacturing methods
Biopharma Dive
Novartis
Regeneron
drug manufacturing
Zaltrap
Eylea
Flag link:
The 3 Most Disappointing Drug Launches of All Time
The 3 Most Disappointing Drug Launches of All Time
Motley Fool
drug launches
MannKind
Afrezza
Sanofi
Zaltrap
Vivus
Arena Pharmaceuticals
Qsymia
Belviq
Flag link:
FDA Approves Sanofi SA's and Regeneron Pharmaceuticals Inc's Zaltrap for Metastatic Colorectal Cancer
FDA Approves Sanofi SA's and Regeneron Pharmaceuticals Inc's Zaltrap for Metastatic Colorectal Cancer
Reuters
FDA
Sanofi
Regneron
Zaltrap
colorectal cancer
Flag link:
Final NICE guidance rejects Sanofi's Zaltrap in colorectal cancer
Final NICE guidance rejects Sanofi's Zaltrap in colorectal cancer
First Word Pharma
NICE
Sanofi
colorectal cancer
Zaltrap
Flag link:
Why Regeneron Pharmaceuticals Has A Bright Future Ahead
Why Regeneron Pharmaceuticals Has A Bright Future Ahead
Seeking Alpha
Regeneron
Arcalyst
Eylea
Zaltrap
Flag link:
3 Drug Disappointments From 2012
3 Drug Disappointments From 2012
Motley Fool
Zaltrap
Sanofi
Amarin
Vascepa
Qsymia
Arena Pharmaceuticals
Flag link:
10 top drug launch disasters
10 top drug launch disasters
Fierce Pharma
drug launches
Rare Disease Therapeutics
Anascorp
AstraZeneca
Brilinta
Somaxon
Silenor
Sanofi
Multaq
Savient
Krystexxa
XenoPort
Horizant
Human Genome Sciences
Benlysta
Zaltrap
Dendreon
Provenge
KV Pharmaceutical
Makena
Flag link:
Sanofi Wins EU Backing for Drugs Against Diabetes, Cancer
Sanofi Wins EU Backing for Drugs Against Diabetes, Cancer
Bloomberg
Lyxumia
diabetes
Zaltrap
colorectal cancer
Flag link:
This Top-Dollar Drug Hits the Discount Rack
This Top-Dollar Drug Hits the Discount Rack
Motley Fool
Sanofi
Dendreon
Regeneron
Zaltrap
Flag link:
Sanofi Wins EU Backing for New Drugs Against Diabetes and Cancer
Sanofi Wins EU Backing for New Drugs Against Diabetes and Cancer
Bloomberg
Sanofi
Europe
diabetes
Zaltrap
colorectal cancer
Lyxumia
Flag link:
Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection
Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection
NY Times, NY
drug pricing
Sanofi
Sloan Kettering
colon cancer
Zaltrap
Flag link:
Sanofi: A Long-Term Winner On These FDA Approvals
Sanofi: A Long-Term Winner On These FDA Approvals
Seeking Alpha
Sanofi
FDA
Aubagio
Zaltrap
Flag link:
3 Drugs Approved, but Only 1 Matters
3 Drugs Approved, but Only 1 Matters
Motley Fool
FDA
drug approvals
Regeneron
Arcalyst
Eyelea
Novartis
Sanofi
Zaltrap
Flag link:
Why Regeneron May Not Profit Much From Today's FDA Approval
Why Regeneron May Not Profit Much From Today's FDA Approval
Forbes
Regeneron
Zaltrap
colorectal cancer
Flag link:
FDA approves Sanofi/Regeneron colon cancer drug
FDA approves Sanofi/Regeneron colon cancer drug
Reuters
FDA
Sanofi
Regeneron
colon cancer
Zaltrap
Flag link:
Top 10 late-stage cancer drugs in 2012
Top 10 late-stage cancer drugs in 2012
Fierce Biotech
BB1608
Boston Biomedical
Dainippon Sumitomo
cabozantinib
Exelixis
ONYX Pharmaceuticals
Carfilzomib
Medivation
Astellas
Enzalutamide
Ariad Pharmaceuticals
Ponatinib
Bayer
regorafenib
Oncovex
Amgen
Roche
Genentech
T-DM1
Immunogen
Aveo
tivozanib
Zaltrap
Sanofi
Regeneron
Flag link:
Priority Review for Zaltrap
Priority Review for Zaltrap
Yahoo/Zacks
Zaltrap
Regeneron
Sanofi
colorectal cancer
Flag link:
Sanofi Singles Out Top Pipeline Prospects, New Cost Cuts
Sanofi Singles Out Top Pipeline Prospects, New Cost Cuts
Motley Fool
Sanofi
Genzyme
Kynamro
Visamerin/Mulsevo
Zaltrap
Lemtrada
Aubagio
Lyxumia
Flag link:
Regeneron's VENICE Study to Continue
Regeneron's VENICE Study to Continue
Yahoo/Zacks
Regeneron
Zaltrap
prostate cancer
Sanofi
Flag link:
Sanofi, Regeneron report progress with cancer drug
Sanofi, Regeneron report progress with cancer drug
Marketwatch
Sanofi
Regeneron
Zaltrap
colorectal cancer
Flag link:

Pages